Status:
UNKNOWN
Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy
Lead Sponsor:
National Cancer Institute, Naples
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to develop and validate a patient-reported-outcome instrument (PROFTC-I: Patient Reported Outcome Financial Toxicity in Cancer - Italy) able to describe and measure financial ...
Detailed Description
The project will be conducted according to the methodology delineated by the International Society for Pharmacoeconomics and Outcome Research (ISPOR) Patient Reported Outcomes Content Validity Good Re...
Eligibility Criteria
Inclusion
- Adult patients (\>18 years)
- Histologically or cytologically confirmed diagnosis of any type of solid cancer or haematological malignancy
- Written Informed Consent provided
- Medical treatment (chemotherapy, target agents, immunotherapy, hormonal treatment, radiotherapy or combinations of such therapies) ongoing or terminated within the previous 3 months.
- Caregivers of patients who meet the above criteria
Exclusion
- Patients with major cognitive dysfunction or psychiatric disorders
- Patients who have never received anticancer medical or radiation treatment
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT03473379
Start Date
March 1 2018
End Date
July 1 2024
Last Update
March 24 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda dei Colli
Napoli, Italy
2
Istituto Nazionale Tumori, IRCCS Fondazione Pascale
Napoli, Italy
3
Istituto Nazionale Tumori Regina Elena - IRCCS - IFO
Roma, Italy
4
Policlinico Universitario Campus Biomedico
Roma, Italy